History of Bretisilocin in Timeline

Share: FB Share X Share Reddit Share Reddit Share
Bretisilocin

Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.

2022: First Description in Literature

In 2022, Bretisilocin was first described in the scientific literature.

X (Twitter) Facebook

June 2025: Phase 2 Clinical Trials

In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.

X (Twitter) Facebook

August 2025: Acquisition by AbbVie

In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.

X (Twitter) Facebook
Home | Recently Updated | Most Popular | Birthdays

About Popular Timelines

Discover the past with PopularTimelines.com, your go-to platform for exploring the rich history of famous people, events, places, and more, all presented in an engaging timeline format. Whether you're a history buff or just curious about significant milestones, Popular Timelines provides a visually captivating way to learn and explore. Navigate through detailed timelines that cover everything from historical events to the lives of renowned individuals, offering a comprehensive view of the world's legacy. Stay informed and enlightened with accurate, well-researched content that brings history to life.

Follow Us